Emerging Lipid-Lowering Therapies: A Comprehensive Review of Novel Agents Targeting Hyperlipidemia

Background: Hyperlipidemia is a major risk factor for cardiovascular diseases, often necessitating long-term pharmacological intervention to manage cholesterol and triglyceride levels. Traditional treatments, such as statins and niacin, have been effective but are often associated with adverse effects and limited efficacy in certain populations. The development of novel lipid-lowering therapies, targeting specific mechanisms of lipid metabolism, offers new potential for personalized treatment approaches. Methods: This review examines a range of emerging pharmacological therapies for hyperlipidemia, including PCSK9 inhibitors, CETP inhibitors, ACL inhibitors, MTP inhibitors, APOC3 inhibitors, ANGPTL inhibitors, and antisense oligonucleotides (ASOs). Each class of drugs was evaluated for its mechanism of action, efficacy in clinical trials, and associated side effects. Relevant clinical studies were analyzed to compare their efficacy in reducing LDL cholesterol, raising HDL cholesterol, and improving overall cardiovascular outcomes. Results and Discussion: PCSK9 inhibitors (Alirocumab and Evolocumab) demonstrated a significant 60% reduction in LDL cholesterol levels and improved cardiovascular outcomes when combined with statins. CETP inhibitors, such as Dalcetrapib, increased HDL cholesterol by 31% without affecting LDL cholesterol levels, while Bempedoic acid, an ACL inhibitor, proved effective in lowering cholesterol and glucose levels, especially in statin-intolerant patients. APOC3 inhibitors (Volanesorsen, Olezarsen) successfully reduced triglyceride levels by inhibiting lipoprotein lipase activity. ASO drugs (Mipomersen, Inclisiran) provided gene-targeted therapy for primary hypercholesterolemia, offering a novel therapeutic avenue. ANGPTL inhibitors impacted triglyceride metabolism, and icosapent ethyl significantly reduced cardiovascular risk in statin-treated individuals. These novel therapies have demonstrated significant reductions in LDL and triglyceride levels while improving HDL cholesterol and reducing cardiovascular risks.